Doxycycline should not normally be used for STI post-exposure prophylaxis

Doxycycline should not normally be used for STI post-exposure prophylaxis

November 10 2017 Doxycycline should not be used for post-exposure prophylaxis (PEP) for sexually...

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

October 31 2017 The medicines regulator has issued four drug safety updates (DRU) relating to...

Pneumococcal polysaccharide vaccine shortage prompts advice about prioritisation

Pneumococcal polysaccharide vaccine shortage prompts advice about prioritisation

October 23 2017 A shortage of the pneumococcal polysaccharide vaccine has promoted a Chief...

PHE issues guide on sepsis in children for health visitors and school nurses

PHE issues guide on sepsis in children for health visitors and school nurses

October 10 2017 A new guide setting out information around sepsis in children has been published...

MHRA issues Drug Safety Updates for loperamide and miconazole

MHRA issues Drug Safety Updates for loperamide and miconazole

October 4 2017 The medicines regulator, the MHRA, has issued Drug Safety Updates on two...

  • Doxycycline should not normally be used for STI post-exposure prophylaxis

    Doxycycline should not normally be used for STI post-exposure prophylaxis

    Friday, 10 November 2017 17:31
  • MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    Tuesday, 31 October 2017 20:27
  • Pneumococcal polysaccharide vaccine shortage prompts advice about prioritisation

    Pneumococcal polysaccharide vaccine shortage prompts advice about prioritisation

    Monday, 23 October 2017 09:39
  • PHE issues guide on sepsis in children for health visitors and school nurses

    PHE issues guide on sepsis in children for health visitors and school nurses

    Tuesday, 10 October 2017 13:34
  • MHRA issues Drug Safety Updates for loperamide and miconazole

    MHRA issues Drug Safety Updates for loperamide and miconazole

    Wednesday, 04 October 2017 17:04

a blood pressure monitor imageSeptember 4 2017

Prescription strength doses of ibuprofen are associated with increased blood pressure and hypertension compared to celecoxib in patients with osteoarthritis or rheumatoid arthritis. The study has also found ibuprofen to be associated with an increased risk of cardiovascular disease.

 The findings are from the US-based PRECISION-ABPM study, which was designed to determine the blood pressure effects of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib compared to the non-selective NSAIDs naproxen and ibuprofen. It involved 444 patients, of whom 408 (92%) had osteoarthritis and 36 (8%) had rheumatoid arthritis. All patients had evidence of, or were at increased risk for, coronary artery disease.

Patients were randomised to receive celecoxib (100-200 mg twice a day), ibuprofen (600-800 mg three times a day), or naproxen (375-500 mg twice a day) with matching placebos. The primary endpoint was the change from baseline in 24-hour ambulatory blood pressure after four months.

Celecoxib decreased the average systolic blood pressure measured over 24 hours by -0.3 mmHg while ibuprofen and naproxen increased it by 3.7 and 1.6 mmHg, respectively. The resulting difference of -3.9 mmHg between celecoxib and ibuprofen was significant (p=0.009).

The results were presented at the European Society of Cardiology meeting.

Principal investigator Prof Frank Ruschitzka of the University Heart Centre, Zurich, Switzerland, said: “While celecoxib and naproxen produced either a slight decrease (celecoxib) or a relatively small increase (naproxen) in blood pressure, ibuprofen was associated with a significant increase in ambulatory systolic blood pressure of more than 3 mmHg.”

In addition, “patients receiving ibuprofen had a 61% higher incidence of de novo hypertension compared to those receiving celecoxib.

“PRECISION-ABPM clearly demonstrates that NSAIDs, particularly ibuprofen, may be not as safe as previously thought … since decreasing systolic blood pressure by just 2 mmHg lowers stroke mortality by 10% and ischaemic heart disease mortality by 7%, increases in systolic blood pressure associated with NSAIDs as observed in PRECISION-ABPM should be considered clinically relevant.”

The study was funded by Pfizer.

Link:
ESC announcement         

Clinical News

November 16 2017 Scotland’s new General Medical Services contract could “reduce workload pressures and re-establish general practice as an attractive career choice,” the BMA has...
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...